Track Marker Therapeutics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Marker Therapeutics, Inc. MRKR · Stock Open Marker Therapeutics, Inc. in new tab

0.8700 USD
EPS
-0.42
P/B
1.19
ROE
-76.87
Beta
1.62
Target Price
7.87 USD
Loading chart...
Key Metrics
Earnings dateMarch 24, 2027
EPS-0.42
Book Value0.73
Price to Book1.19
% Insiders5.493%
Growth
Revenue Growth-0.51%
Estimates
Forward P/E-1.64
Forward EPS-0.53
Target Mean Price7.87

DCF valuation

Model fair value for Marker Therapeutics, Inc. (MRKR)
Result
Sign in to run the valuation for MRKR.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
3 analysts · consensus None · mean target 7.87 USD (low 5.60, high 10.00) · as of 14 Nov 2026
Low 5.60
Mean 7.87
High 10.00
Price 0.8700
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Marker Therapeutics, Inc. Logo Marker Therapeutics, Inc. Analysis (MRKR)

United States Health Care Official Website Stock

Is Marker Therapeutics, Inc. a good investment? Marker Therapeutics, Inc. (MRKR) is currently trading at 0.8700 USD. Market analysts have a consensus price target of 7.87 USD. This suggests a potential upside from current levels.

Earnings Schedule: Marker Therapeutics, Inc. is expected to release its next earnings report on March 24, 2027. The market consensus estimate for Forward EPS is -0.53.

Investor FAQ

Does Marker Therapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Marker Therapeutics, Inc.?

Marker Therapeutics, Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be March 24, 2027. The company currently has a trailing EPS of -0.42.

Company Profile

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company was formerly known as TapImmune, Inc. and changed its name to Marker Therapeutics, Inc. in October 2018. Marker Therapeutics, Inc. was founded in 1999 and is headquartered in Houston, Texas.

Exchange Ticker
FRA (Germany) GX1N.F
MUN (Germany) GX1N.MU
NMS (United States) MRKR
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
June 28, 2007 0.4
July 27, 2009 1:10
Feb. 25, 2014 1:100
Sept. 16, 2016 0.08
Jan. 27, 2023 1:10
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion